<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898754</url>
  </required_header>
  <id_info>
    <org_study_id>14124-SCH</org_study_id>
    <nct_id>NCT01898754</nct_id>
  </id_info>
  <brief_title>Oligonucleotide Ligation Assay (OLA) Resistance Study</brief_title>
  <acronym>OLA</acronym>
  <official_title>Drug-resistance Testing in Kenya to Improve ART Suppression of HIV Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to gauge improvements in the rate of durable suppression of viral&#xD;
      replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope&#xD;
      Center in Kenya, and to determine the cost-effectiveness of implementing this strategy at&#xD;
      Coptic Hope Center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Durable suppression of HIV replication is critical to (1) improving the health of infected&#xD;
      individuals, (2) to reducing HIV transmission to sexual partners and from mothers to their&#xD;
      infants, and (3) to maintaining the effectiveness of the current 1st-line non-nucleoside&#xD;
      reverse transcriptase inhibitors (NNRTI)- based ART. Across multiple trials, individuals with&#xD;
      NNRTI-resistance, even at low-concentrations, have substantially greater virologic failure&#xD;
      when treated with NVP- vs PI-ART. A cost-effective strategy is needed to detect and manage&#xD;
      ARV-resistant HIV infections. A simple low-cost innovative assay the investigators developed&#xD;
      and successfully transferred to Asian and African countries (oligonucleotide ligation assay&#xD;
      (OLA)) can detect NNRTI+lamivudine (3TC) resistant HIV using reagents that costs&#xD;
      &lt;$7.00/person. Furthermore, detection of NNRTI-resistance by OLA is highly (P&lt;0.001)&#xD;
      associated with virologic failure of nevirapine (NVP)-ART in two retrospective studies; one&#xD;
      of Thai women who had been previously randomized to single-dose NVP and the second of&#xD;
      ARV-naïve Kenyan adults.&#xD;
&#xD;
      The investigators hypothesize that implementation of OLA into routine care will allow Kenyan&#xD;
      clinicians to appropriately target protease inhibitor (PI)-based ART and improve rates of&#xD;
      durable suppression of viral replication, and thus improve CD4 cell gains and individuals'&#xD;
      health, reduce the transmission of ARV-resistant HIV within the community, and maintain the&#xD;
      utility of NNRTI-ART. In addition, the investigators hypothesize that programmatically&#xD;
      OLA-guided ART will be more cost-efficient compared to the current strategy of empiric use of&#xD;
      NNRTI-ART as initial treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Overall Difference in Rates of Virologic Failure With OLA-guided ART vs. Standard of Care</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint will be a comparison of the rates of viral non-suppression &gt;400 copies/mL between study arms at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Difference in Virologic Failure Among the Subgroup of ARV-naïve Participants With Transmitted Drug-resistance (TDR) Associated With Use of OLA-guided ART vs. SOC</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference in Virologic Failure Among the Subgroup of Participants Referred to Hope Center With Previous or Ongoing ARV Use Associated With Use of OLA-guided ART vs. SOC</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of TDR by Consensus Sequencing and OLA</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subgroup With TDR With Virologic Failure by Randomization Arm</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of TDR Increase in the Coptic Clinic</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Medical Resource Utilization During the One-year Trial Period</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An Assessment the Short-term Cost-effectiveness of OLA-guided Testing</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An Assessment of the Potential Long-term Cost-effectiveness of OLA-guided Testing Over a Patient's Lifetime</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Whether Low-level ARV Resistance (&lt;5%) Detected by PYRO But Not by OLA is Associated With Virologic Failure</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Descriptions of Technology Transfer of OLA to the Hope Center Laboratory, Including Intra- and Inter-assay the Reproducibility, and Discussion of Obstacles and Possible Solutions</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>A Comparison of OLA Results Obtained Using DBS in Kenya to Retesting of Same Specimens With Input of Viral Templates Measured in Seattle</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>A Comparison of Rates of Resistance Detected Across Codons by OLA vs. Consensus Sequencing in Seattle</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">991</enrollment>
  <condition>HIV Positive</condition>
  <arm_group>
    <arm_group_label>Pre-ART Oligonucleotide Assay (OLA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No OLA (Standard of Care [SOC])</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-ART Oligonucleotide Assay (OLA)</intervention_name>
    <description>Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART</description>
    <arm_group_label>Pre-ART Oligonucleotide Assay (OLA)</arm_group_label>
    <other_name>Pre-ART OLA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed HIV infection&#xD;
&#xD;
          2. &gt;2 years of age&#xD;
&#xD;
          3. Qualifying for 1st-line ART based on Kenyan Guidelines&#xD;
&#xD;
          4. Plan to reside in area for &gt;1 year&#xD;
&#xD;
          5. Adult patient or parent of minor agrees to study and provides informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received ART previously from Hope Center&#xD;
&#xD;
          2. Ongoing ART&#xD;
&#xD;
          3. Plan to start 2nd-line ART&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Frenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Seattle Children's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael H Chung, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Global Health, University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coptic Hospital</name>
      <address>
        <city>Maseno</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coptic Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>October 18, 2021</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Michael Chung</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Transmitted Drug Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pre-ART Oligonucleotide Assay (OLA)</title>
          <description>Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)&#xD;
Pre-ART Oligonucleotide Assay (OLA): Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART</description>
        </group>
        <group group_id="P2">
          <title>No OLA (Standard of Care [SOC])</title>
          <description>The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
                <participants group_id="P2" count="497"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="403"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-ART Oligonucleotide Assay (OLA)</title>
          <description>Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)&#xD;
Pre-ART Oligonucleotide Assay (OLA): Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART</description>
        </group>
        <group group_id="B2">
          <title>No OLA (Standard of Care [SOC])</title>
          <description>The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="492"/>
            <count group_id="B2" value="495"/>
            <count group_id="B3" value="987"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="32" upper_limit="46"/>
                    <measurement group_id="B2" value="37" lower_limit="30" upper_limit="45"/>
                    <measurement group_id="B3" value="37" lower_limit="31" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="321"/>
                    <measurement group_id="B3" value="641"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="492"/>
                    <measurement group_id="B2" value="495"/>
                    <measurement group_id="B3" value="987"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="492"/>
                    <measurement group_id="B2" value="495"/>
                    <measurement group_id="B3" value="987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Overall Difference in Rates of Virologic Failure With OLA-guided ART vs. Standard of Care</title>
        <description>The primary endpoint will be a comparison of the rates of viral non-suppression &gt;400 copies/mL between study arms at 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-ART Oligonucleotide Assay (OLA)</title>
            <description>Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)&#xD;
Pre-ART Oligonucleotide Assay (OLA): Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART</description>
          </group>
          <group group_id="O2">
            <title>No OLA (Standard of Care [SOC])</title>
            <description>The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Overall Difference in Rates of Virologic Failure With OLA-guided ART vs. Standard of Care</title>
          <description>The primary endpoint will be a comparison of the rates of viral non-suppression &gt;400 copies/mL between study arms at 12 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference in Virologic Failure Among the Subgroup of ARV-naïve Participants With Transmitted Drug-resistance (TDR) Associated With Use of OLA-guided ART vs. SOC</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference in Virologic Failure Among the Subgroup of Participants Referred to Hope Center With Previous or Ongoing ARV Use Associated With Use of OLA-guided ART vs. SOC</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of TDR by Consensus Sequencing and OLA</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subgroup With TDR With Virologic Failure by Randomization Arm</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of TDR Increase in the Coptic Clinic</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimates of Medical Resource Utilization During the One-year Trial Period</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>An Assessment the Short-term Cost-effectiveness of OLA-guided Testing</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>An Assessment of the Potential Long-term Cost-effectiveness of OLA-guided Testing Over a Patient's Lifetime</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Whether Low-level ARV Resistance (&lt;5%) Detected by PYRO But Not by OLA is Associated With Virologic Failure</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Descriptions of Technology Transfer of OLA to the Hope Center Laboratory, Including Intra- and Inter-assay the Reproducibility, and Discussion of Obstacles and Possible Solutions</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>A Comparison of OLA Results Obtained Using DBS in Kenya to Retesting of Same Specimens With Input of Viral Templates Measured in Seattle</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>A Comparison of Rates of Resistance Detected Across Codons by OLA vs. Consensus Sequencing in Seattle</title>
        <time_frame>15 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pre-ART Oligonucleotide Assay (OLA)</title>
          <description>Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)&#xD;
Pre-ART Oligonucleotide Assay (OLA): Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART</description>
        </group>
        <group group_id="E2">
          <title>No OLA (Standard of Care [SOC])</title>
          <description>The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastric Ulcers</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastrointestinal distress</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hemorrhoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cryptococcal Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Esophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Menigitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kaposi Sarcoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bell's Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Childbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Blocked Fallopian Tubes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Fibroids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Threatened Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Nail Discoloration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Bloody Stool</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Mouth Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Childbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Nail Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Lisa Frenkel</name_or_title>
      <organization>University of Washington</organization>
      <phone>+1 206 987-5140</phone>
      <email>lfrenkel@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

